Amblyopia, the leading cause of monocular vision impairment in children, is a treatable condition when identified early. Despite advancements in nonsurgical therapies-including patching, atropine penalization, and emerging digital tools-significant disparities persist in who receives timely diagnosis and effective treatment. This commentary explores the intersection of amblyopia treatment and health disparities, synthesizing current evidence on how race, socioeconomic status, insurance coverage, age of diagnosis, and geography influence diagnosis, treatment, and outcomes. A keyword-based search across PubMed and Embase revealed a stark underrepresentation of disparities-focused research within the broader amblyopia literature. While recent studies suggest growing awareness, disparities persist in early detection, access to specialists, and treatment efficacy-particularly among children with public insurance, racial and ethnic minorities, and those in underserved regions. This review highlights key themes: early diagnosis is a strong predictor of successful treatment, access to screening alone does not ensure equitable care, and equity must be central to research and innovation as the field embraces digital and adult-targeted therapies. To ensure emerging treatments benefit all patients, future research must prioritize representative populations and use frameworks rooted in health equity. Deliberate efforts to address systemic barriers are essential to achieving equitable amblyopia care across the lifespan.
Medina et al. (Mon,) studied this question.